Susan E. Bates
National Institutes of Health
15 Papers
246 Citations
Susan E. Bates is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Drug resistance & ATP-binding cassette transporter. The author has an hindex of 14, co-authored 15 publications.
Chat about Author
Papers
Multidrug resistance in cancer: role of ATP–dependent transporters
TL;DR: The ability to predict and circumvent drug resistance is likely to improve chemotherapy, and it has become apparent that resistance exists against every effective drug, even the authors' newest agents.
•Journal Article
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
Yasumasa Honjo,Christine A. Hrycyna,Qing-Wu Yan,Wilma Y. Medina-Pérez,Robert W. Robey,Anne van de Laar,Thomas Litman,Michael Dean,Susan E. Bates +8 more
TL;DR: It is suggested that amino acid 482 has a crucial role in MXR/BCRP/ABCP function and that mutation of a single amino acid residue significantly changes substrate specificity, thus altering the drug resistance phenotype.
•Journal Article
Rhodamine efflux patterns predict p-glycoprotein substrates in the national cancer institute drug screen
J S Lee,Kenneth D. Paull,Manuel Alvarez,Curtis Hose,Anne Monks,Michael R. Grever,A T Fojo,Susan E. Bates +7 more
TL;DR: Using the rhodamine efflux data as a seed for COMPARE analysis with the cytotoxicity data on > 30,000 compounds in the National Cancer Institute drug screen database, hundreds of compounds with high correlation coefficients were identified.
366
Single nucleotide polymorphisms modify the transporter activity of ABCG2
Kuniaki Morisaki,Robert W. Robey,Csilla Özvegy-Laczka,Yasumasa Honjo,Orsolya Polgar,Kenneth Steadman,Balázs Sarkadi,Susan E. Bates +7 more
TL;DR: The results suggest that the Q141K SNP affects the transport efficiency of ABCG2 and may result in altered pharmacokinetics or drug-resistance profiles in clinical oncology.
240
•Journal Article
Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576
Manish Agrawal,Jame Abraham,Frank M. Balis,Maureen Edgerly,Wilfred D. Stein,Susan E. Bates,Tito Fojo,Clara C. Chen +7 more
TL;DR: This study provides convincing evidence of the existence of XR9576-inhibitable (99m)Tc-sestamibi efflux in a large fraction of drug resistant tumors and provides an efficient way to inhibit this efflux and offers the potential to increase drug exposure in human cancer.
147